Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).
Hypofractionated radiotherapy showed no clear difference in overall survival for subgroup aged ≥ 60 years glioblastoma compared with daily conventionally fractionated radiotherapy (high certainty).
Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).
Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of breast cancer compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of transient ischaemic attack compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of cerebrovascular accident compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of myocardial infarction compared with no HRT (very low certainty).
The review found no eligible studies for this question.
Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).
Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).